Dual antithrombotic therapy after percutaneous coronary intervention

Watch Dr Christopher Cannon discuss his study: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey

Speaker

Christopher Cannon

Baim Institute for Clinical Research

Massachusetts, USA

Topic

In patients with atrial fibrillation who have had a percutaneous coronary intervention, the current standard practice is to prescribe “triple therapy” i.e. warfarin plus two antiplatelet agents including an aspirin. However, this is associated with a high risk of bleeding. This ground-breaking trial compares triple therapy with “dual therapy” (dabigatran plus one antiplatelet agent).

View abstract  access full paper

  • Target audience
    This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.
  • Learning objectives
    • Describe outcomes from new data regarding the impact on bleeding and thrombotic events of dual therapy with dabigatran and a P2Y12 inhibitor as compared with triple therapy with warfarin,  a P2Y12 inhibitor and aspirin in this patient population
  • Disclosures
    Prof John Camm:
    • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    • Consultant (retained) for: Boehringer Ingelheim
    • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer
    Dr Christopher Cannon:
    • Research grants from Amgen, Arisaph, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck and Takeda;
    • Consulting fees from Alnylam, Amgen, Amarin, Arisaph, Astra Zeneca, BI, BMS, Eisai, GlaxoSmithKline, Kowa, Lipimedix, Merck, Pfizer, Regeneron, Sanofi, and Takeda.

    Staff and reviewer disclosures

    PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
  • Funding
    This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.